Celmatix Company
.jpg)
Celmatix is a next-generation women’s health company transforming the way women and their physicians leverage genomics and data to make more informed, proactive reproductive health decisions. Their products include Polaris, Fertilome genetic test and MyFertility Compass. Celmatix's lead program aims to protect the ovary from chemotherapy-induced ovarian failure (CIOF). For the 1.9 million pre-menopausal women diagnosed with cancer, the need is critical, urgent, and unmet.
.png)
.jpg)
Total Funding:
$53,660,000
Headquarters:
New York, New York, United States
Funding Status:
Early Stage Venture
Employee Number:
11-50
Estimated Revenue:
$10M to $50M
Investment Stage:
N/A
Last Funding Type:
Venture - Series Unknown
Number Of Exists:
Venture - Series Unknown
Technology:
Longevity FemTech
Investor Type:
Company
Last Funding Date:
2019-04-01
Investors Number:
7
Founded Date:
01-01-2009
Industry:
Reproductive Health & Contraception